Advanced cancer patients at the VA will now have access to the company's blood-based PlasmaSelect 64 test as well as the CancerSelect 125 tissue test.
The partners have formed a public/private partnership to foster collaboration and data integration between different institutes researching brain trauma.
The VA has been steadily increasing its capacity to whole-genome sequence enrollees, and may now sequence as many as 30,000 individuals over the next two years.
The deal replaces an existing cancer testing contract to include PGDx's CancerSelect 125 test for pan-cancer tumor profiling.
VA patients will now have access to Polymedco's colorectal cancer screening products, including the Epigenomics Epi proColon.
The contract provides coverage of ConfirmMDx testing at the Medicare rate for veterans within the VA health system.
The company will apply artificial intelligence to a large clinical and genomic dataset from VA records in order to support personalized clinical decision making.
The new partnership will make data from more than 9 million anonymized veterans' medical records available for research.
The company has been working with the VA since 2013, when it it received a contract to provide sequencing and data analysis for enrollees in the Million Veteran Program.
Announced this month, the project brings together CPTAC, the VA, and DoD, and has as its initial goal the proteogenomic analysis of 8,000 lung cancer patients.
Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.
DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.
A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.
In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.